))
VAXXED: And the winner is... with OneVentures and Ose Immunotherapeutics
Manage episode 452109727 series 3594399
Innhold levert av Soundcraft Media. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Soundcraft Media eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Moderna and BioNTech are getting all of the attention with their phase 3 clinical trials for lung cancer and melanoma. But someone else is already further ahead.
French company Ose Immunotherapeutics has already done a phase 3 study for non small cell lung cancer, and if the final run of work confirms that data it will have the first cancer vaccine on the market in 2028.
And it's results like those emerging from Ose that are inspiring investors to start getting set for a cancer vaxxed future.
In our final episode of VAXXED we feature OneVentures partner Dr. Jeannie Joughin and Ose Immunotherapeutics CEO Nicolas Poirier.
Produced by Rachel Williamson and Charis Palmer. Music and effect credits to Ziso, Inspector J, Seth Parson and Boom Library.
Kapitler
1. VAXXED: And the winner is... with OneVentures and Ose Immunotherapeutics (00:00:00)
2. OneVentures partner Dr Jeannie Joughin (00:01:50)
3. Ose Therapeutics Nicolas Poirier (00:13:47)
16 episoder
Del
